Effects of the rational use of corticosteroids eye drops for the prevention of ocular toxicity in high-dose cytosine arabinoside therapy

Yakugaku Zasshi

Volumn 119, Issue 3, 1999, Pages 229-235

  Itoh, Mizuki ^a   Aoyama, Takao ^a   Yamamura, Yoshikazu ^a   Nakajima, Katsuyoshi ^a   Nakamura, Kouichi ^a   Kotaki, Hajime ^b   Matsuyama, Tomohiro ^a   Saitoh, Toshiki ^a   Kami, Masahiro ^a   Chiba, Shigeru ^a   Hirai, Hisamaru ^a   Yazaki, Yoshio ^a   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Corticosteroid eye drops; Eye washing; High dose cytosine arabinoside therapy; Ocular toxicity; Rational use

Indexed keywords

ARTIFICIAL TEAR; BALANCED SALT SOLUTION; BETAMETHASONE SODIUM PHOSPHATE; CYTARABINE; EYE DROPS; MITOXANTRONE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG UTILIZATION; EYE PROTECTION; EYE TOXICITY; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; RISK FACTOR; TOPICAL DRUG ADMINISTRATION;

EID: 0033006357     PISSN: 00316903     EISSN: None     Source Type: Journal    
DOI: 10.1248/yakushi1947.119.3_229     Document Type: Article

References (27)

1. Herzig R. H., Wolff S. N., Lazarus H. M., Phillips G. L., Karanes C., Herzig G. P., Blood, 62, 361-369 (1983).
2. Hiddemann W., Ann. Hematol., 62, 119-128 (1991).
3. Ritch P. S., Hansen R. M., Heuer D. K., Cancer, 51, 430-432 (1983).
4. Burns L. J., Semin. Oncol., 19, 492-500 (1992).
5. Tweigeri T. A., Nabholtz J. M., Mackey J. R., Cancer, 78, 1359-1373 (1996).
6. Gressel M. G., Tomsak R. L., Lancet, 2, 273 (1982).
7. Hande K. R., Stein R. S., McDonough D. A., Greco F. A., Wolff S. N., Clin. Pharmacol. Ther., 31, 669-674 (1982).
8. Hopen G., Mondino B. J., Johnson B. L., Chervenick P. A., Am. J. Ophthalmol., 91, 500-504 (1981).
9. Kaufman H. E., Capella J. A., Maloney E. D., Robbins J. E., Cooper G. M., Uotila M. H., Arch. Ophthalmol., 72, 535-540 (1964).
10. Barletta J. P., Fanous M. M., Margo C. E., Am. J. Ophthalmol., 113, 587-588 (1992).
11. Gococo K. O., Lazarus H. M., Lass J. H., Cancer, 69, 2866-2867 (1992).
12. Higa G. M., Gockerman J. P., Hunt A. L., Jones M. R., Horne B. J., Cancer, 68, 1691-1693 (1991).
13. Lass J. H., Lazarus H. M., Reed M. D., Herzig R. H., Am. J. Ophthalmol., 94, 617-621 (1982).
14. Friedland S., Loya N., Shapiro A., Ann. Ophthalmol., 25, 290-291 (1993).
15. Zimmerman T. J., Kooner K. S., Kandarakis A. S., Ziegler L. P., Arch. Opthalmol., 84, 551-553 (1984).
16. Boos J., Bomelburg T., Gerding H., Jurgens H., Int. J. Clin. Pharmacol. Ther. Toxicol., 31, 593-596 (1993).
17. Prooijen R. V., Kleijn E., Haanen C., Clin. Pharmacol. Ther., 21, 744-750 (1977).